TOT BIOPHARM International Co Ltd
HKEX:1875
Income Statement
Earnings Waterfall
TOT BIOPHARM International Co Ltd
Income Statement
TOT BIOPHARM International Co Ltd
| Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Interest Expense |
2
|
6
|
7
|
5
|
5
|
7
|
10
|
0
|
|
| Revenue |
76
N/A
|
235
+208%
|
442
+88%
|
588
+33%
|
781
+33%
|
973
+25%
|
1 098
+13%
|
1 067
-3%
|
|
| Gross Profit | |||||||||
| Cost of Revenue |
(49)
|
(63)
|
(72)
|
(126)
|
(207)
|
(272)
|
(316)
|
(308)
|
|
| Gross Profit |
27
N/A
|
172
+526%
|
371
+115%
|
462
+25%
|
574
+24%
|
701
+22%
|
782
+12%
|
759
-3%
|
|
| Operating Income | |||||||||
| Operating Expenses |
(283)
|
(322)
|
(409)
|
(510)
|
(595)
|
(684)
|
(744)
|
(740)
|
|
| Selling, General & Administrative |
(76)
|
(137)
|
(263)
|
(399)
|
(506)
|
(589)
|
(683)
|
(692)
|
|
| Research & Development |
(187)
|
(196)
|
(129)
|
(131)
|
(83)
|
(100)
|
(68)
|
(69)
|
|
| Depreciation & Amortization |
(31)
|
0
|
(25)
|
0
|
(24)
|
0
|
(16)
|
0
|
|
| Other Operating Expenses |
11
|
11
|
9
|
21
|
18
|
6
|
23
|
20
|
|
| Operating Income |
(255)
N/A
|
(150)
+41%
|
(38)
+74%
|
(48)
-24%
|
(21)
+55%
|
17
N/A
|
38
+121%
|
18
-53%
|
|
| Pre-Tax Income | |||||||||
| Interest Income Expense |
(0)
|
(11)
|
(9)
|
(3)
|
(1)
|
(6)
|
(10)
|
(10)
|
|
| Non-Reccuring Items |
(5)
|
(1)
|
(3)
|
1
|
(15)
|
(3)
|
7
|
(1)
|
|
| Pre-Tax Income |
(261)
N/A
|
(162)
+38%
|
(50)
+69%
|
(49)
+1%
|
(38)
+24%
|
9
N/A
|
35
+288%
|
7
-79%
|
|
| Net Income | |||||||||
| Tax Provision |
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(261)
|
(162)
|
(50)
|
(49)
|
(38)
|
9
|
35
|
7
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(261)
N/A
|
(162)
+38%
|
(50)
+69%
|
(49)
+1%
|
(38)
+23%
|
9
N/A
|
35
+288%
|
7
-79%
|
|
| EPS (Diluted) |
-0.46
N/A
|
-0.28
+39%
|
-0.08
+71%
|
-0.07
+12%
|
-0.05
+29%
|
0.01
N/A
|
0.05
+400%
|
0.01
-80%
|
|